Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€0.77

€0.77

7.500%
0.0535
7.500%
€6.53
 
26.04.24 / Tradegate WKN: A2N4RX / Symbol: GRTS / Name: Gritstone Oncology / Stock / Pharmaceuticals / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Gritstone Oncology Inc Stock

A very strong showing by Gritstone Oncology Inc today, with an increase of €0.054 (7.500%) compared to yesterday's price.
Based on 2 Buy predictions and 2 Sell predictions the sentiment towards Gritstone Oncology Inc is rather balanced.
With a target price of 6 € there is potential for a 681.76% increase which would mean more than doubling the current price of 0.77 € for Gritstone Oncology Inc.
Our community identified positive and negative aspects for Gritstone Oncology Inc stock for the coming years. 7 users see the criterium "Worthwhile Investment for the next years" as a plus for the Gritstone Oncology Inc stock. On the other hand our users think that "Market Position" could be a problem in the future.

Pros and Cons of Gritstone Oncology Inc in the next few years

Pros
?
G***** c******* t* c**********
?
M***** P*******
?
C******** o* t** e**********
Cons
?
S********** s********
?
W********* I********* f** t** n*** y****
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Gritstone Oncology Inc vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Gritstone Oncology Inc 7.500% 11.232% -68.154% -65.271% -58.692% -90.436% -
Rockwell Medical Inc. 1.620% 3.561% -4.362% -26.923% -20.034% -85.152% -96.854%
Avid Bioservices Inc 3.170% 9.244% 1.563% -61.310% 6.557% -63.068% 49.683%
Innoviva Inc. 2.140% 2.899% 2.899% 30.275% -2.740% 46.392% -

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-11-09

Nur wenige Unternehmen können den Sturm, der sich in der pharmazeutischen Branche abspielt, überleben. Auf der einen Seite stehen die immensen Kosten für Forschung und Entwicklung und auf der anderen Seite der Druck nach mehr bezahlbaren Medikamenten. Für einige Unternehmen, wie Gritstone Oncology (Börsensymbol GRTS), scheint allerdings dieses Szenario eine Gelegenheit zu bieten.

Gritstone Oncology steht finanziell betrachtet vor großen Herausforderungen. Da das Unternehmen noch in der Entwicklungsphase steckt, hat es nur begrenzte Einnahmen aus Produktverkäufen. Gleichzeitig sind die Ausgaben für Forschung und Entwicklung (F&E) – mit Ausgaben von 111,4 Millionen USD, 97,5 Millionen USD und 88,6 Millionen USD in den Jahren 2022, 2021 und 2020 – beträchtlich.

Ein positiver Aspekt der finanziellen Lage von Gritstone Oncology ist die solide Bilanz. Das Unternehmen verfügte zum 31. Dezember 2022 über Vermögenswerte in Höhe von 240,75 Millionen USD und ein Eigenkapital von 170,78 Millionen USD. Das bedeutet, dass das Unternehmen über ausreichende Ressourcen verfügt, um seine laufenden Aktivitäten zu finanzieren.

Comments

Prediction Buy
Perf. (%) -60.88%
Target price 6.430
Change
Ends at 06.03.25

Gritstone bio, Inc. (NASDAQ: GRTS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
Ratings data for GRTS provided by MarketBeat
Show more

Prediction Buy
Perf. (%) -46.03%
Target price 6.633
Change
Ends at 28.09.24

Gritstone bio, Inc. (NASDAQ: GRTS) had its price target raised by analysts at Piper Sandler from $6.00 to $7.00. They now have an "overweight" rating on the stock.
Ratings data for GRTS provided by MarketBeat
Show more

Gritstone bio, Inc. (NASDAQ: GRTS) is now covered by analysts at Evercore ISI. They set an "outperform" rating on the stock.
Ratings data for GRTS provided by MarketBeat
Show more